Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial

This study is a prospective, multicenter, multi-cohort Phase III clinical trial. It primarily enrolls high-risk recurrent esophageal cancer patients who have undergone R0 resection after neoadjuvant chemoimmunotherapy. Eligible patients are stratified based on pathological lymph node status and receive either toripalimab monotherapy as maintenance treatment or clinical observation only.

NCT Number	NCT07332221
Lead Sponsor	Henan Cancer Hospital
Conditions	Esophageal Cancer
Enrollment	435 participants
Start Date	2026-01-20
Primary Completion	2029-10-01 (estimated)
Study Completion	2031-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-12